Results 21 to 30 of about 105,726 (291)

Cambios en la homeostasis de la glucosa y la proliferación de la célula beta pancreática tras el cambio a ciclosporina en la diabetes inducida por tacrolimus

Nefrología, 2015
Antecedentes: El cambio a ciclosporina A podría revertir la diabetes inducida por tacrolimus. Sin embargo, los mecanismos de esta reversibilidad se desconocen. Métodos: Usamos como modelo de diabetes inducida por tacrolimus las ratas Zucker obesas.
Ana Elena Rodríguez-Rodríguez, Javier Triñanes, Esteban Porrini, Silvia Velázquez-García, Cecilia Fumero, María Jose Vega-Prieto, María Luisa Díez-Fuentes, Sergio Luis Lima, Eduardo Salido, Armando Torres   +9 more
doaj   +1 more source

Association between time in therapeutic range of tacrolimus blood concentration and acute rejection within the first three months after lung transplantation

Journal of Pharmaceutical Health Care and Sciences, 2022
Background Tacrolimus is a key drug in immunosuppressive therapy following lung transplantation. The blood tacrolimus levels are likely to fluctuate in the early postoperative period, and failure to maintain the tacrolimus trough level in target ranges ...
Yoshiki Katada, Shunsaku Nakagawa, Kotaro Itohara, Takuya Suzuki, Ryota Kato, Hiroki Endo, Mitsuhiro Sugimoto, Atsushi Yonezawa, Takayuki Nakagawa, Akihiro Ohsumi, Daisuke Nakajima, Hiroshi Date, Tomohiro Terada   +12 more
doaj   +1 more source

Glucose homeostasis changes and pancreatic β-cell proliferation after switching to cyclosporin in tacrolimus-induced diabetes mellitus

Nefrología (English Edition), 2015
Background: Switching to cyclosporin A may result in a reversion of tacrolimus-induced diabetes mellitus. However, mechanisms underlying such a reversion are still unknown.
Ana Elena Rodríguez-Rodríguez, Javier Triñanes, Esteban Porrini, Silvia Velázquez-García, Cecilia Fumero, María Jose Vega-Prieto, María Luisa Díez-Fuentes, Sergio Luis Lima, Eduardo Salido, Armando Torres   +9 more
doaj   +1 more source

Population pharmacokinetics and initial dose optimization of tacrolimus in children with severe combined immunodeficiency undergoing hematopoietic stem cell transplantation

Frontiers in Pharmacology, 2022
The present study aimed to explore the population pharmacokinetics and initial dose optimization of tacrolimus in children with severe combined immunodeficiency (SCID) undergoing hematopoietic stem cell transplantation (HSCT).
Xiao Chen, Dongdong Wang, Feng Zheng, Xiaowen Zhai, Hong Xu, Zhiping Li   +5 more
doaj   +1 more source

Case Report: Acute Pancreatitis Associated With Tacrolimus in Kidney Transplantation and a Review of the Literature

Frontiers in Medicine, 2022
BackgroundDrug-induced pancreatitis is a rare cause of acute pancreatitis. Tacrolimus has been used as an immunosuppressant agent in patients after organ transplantation. However, only a few case reports of tacrolimus-induced acute pancreatitis in kidney
Yixuan Ding, Yixuan Ding, Chang Qu, Chang Qu, Huan He, Feng Cao, Feng Cao, Tongwen Ou, Fei Li, Fei Li   +9 more
doaj   +1 more source

Prevention of graft versus host disease with Hematopoietic Cell Transplantation with Reduced Intensity Conditioning—a comparison of three prophylaxis regimens (tacrolimus/mycophenolate mofetil/cyclophosphamide, tacrolimus/methotrexate/bortezomib or tacrolimus/methotrexate/maraviroc) versus tacrolimu

The Lancet Haematology, 2019
Background. Prevention of GVHD without malignant relapse reflects the overall goal of allogeneic hematopoietic cell transplantation (HCT). Novel regimens utilizing either maraviroc (MVC), bortezomib (BOR), or post-transplant cyclophosphamide (PTCy) have ...
J. Bolaños-Meade, R. Reshef, R. Fraser, M. Fei, S. Abhyankar, Z. Al-Kadhimi, A. Alousi, J. Antin, S. Arai, K. Bickett, Yi-Bin Chen, L. Damon, Y. Efebera, N. Geller, S. Giralt, P. Hari, S. Holtan, M. Horowitz, D. Jacobsohn, Richard J. Jones, J. Liesveld, B. Logan, M. MacMillan, M. Mielcarek, P. Noel, J. Pidala, D. Porter, I. Pusic, R. Sobecks, S. Solomon, D. Weisdorf, Juan Wu, M. Pasquini, J. Koreth   +33 more
semanticscholar   +1 more source

Tacrolimus intrapatient variability in solid organ transplantation: A multiorgan perspective

Pharmacotherapy, 2020
Tacrolimus therapy in solid organ transplant (SOT) recipients is challenging due to its narrow therapeutic window and pharmacokinetic variability both between patients and within a single patient.
Lauren Schumacher, A. Leino, Jeong M. Park   +2 more
semanticscholar   +1 more source

A shared mucosal gut microbiota signature in primary sclerosing cholangitis before and after liver transplantation

Hepatology, EarlyView., 2022
In this study of the gut mucosal microbiota in primary sclerosing cholangitis (PSC), we found consistent microbiota features associated with PSC and recurrent PSC, PSC with inflammatory bowel disease and a persistent gut dysbiosis after liver transplantation Abstract Background and Aims Several characteristic features of the fecal microbiota have been ...
Mikal Jacob Hole, Kristin Kaasen Jørgensen, Kristian Holm, Peder R. Braadland, Malin Holm Meyer‐Myklestad, Asle Wilhelm Medhus, Dag Henrik Reikvam, Alexandra Götz, Krzysztof Grzyb, Kirsten Muri Boberg, Tom Hemming Karlsen, Martin Kummen, Johannes R. Hov   +12 more
wiley   +1 more source

The Clinical Impact of the C0/D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients

Frontiers in Pharmacology, 2020
Tacrolimus is metabolized by CYP3A4 and CYP3A5 enzymes. Patients expressing CYP3A5 (in Caucasian patients about 15% of the population but more frequent in African Americans and Asians) have a dose requirement that is around 50% higher than non-expressers
T. van Gelder, S. Meziyerh, J. Swen, A. D. de Vries, D. Moes   +4 more
semanticscholar   +1 more source

Factors associated with cardiovascular events after simultaneous liver–kidney transplant from the US Multicenter Simultaneous Liver–Kidney Transplant Consortium

Hepatology Communications, EarlyView., 2022
Abstract Cardiovascular disease is a leading complication after both liver and kidney transplantation. Factors associated with and rates of cardiovascular events (CVEs) after simultaneous liver–kidney transplant (SLKT) are unknown. This was a retrospective cohort study of adult SLKT recipients between 2002 and 2017 at six centers in six United Network ...
Jennifer Jo, Gonzalo Crespo, Dyanna Gregory, Jasmine Sinha, Jiaheng Xie, Min Zhang, John Magee, Pranab Barman, Yuval A. Patel, Aaron Schluger, Kara Walters, Scott Biggins, Natalia Filipek, Giuseppe Cullaro, Randi Wong, Jennifer C. Lai, Gabriel J. Perreault, Elizabeth C. Verna, Pratima Sharma, Lisa B. VanWagner   +19 more
wiley   +1 more source